Management of paroxysmal nocturnal hemoglobinuria in CALR mutated post-essential thrombocythemia myelofibrosis: A case report.

Paroxysmal nocturnal hemoglobinuria (PNH) results from the loss of erythrocyte surface proteins, leading to complement activation and its spectrum of effects. We explore this case of a 57-year-old man with post-essential thrombocythemia (ET) myelofibrosis (MF) who developed symptomatic anemia with evidence of hemolysis on lab work. While hemolysis was localized to be intramedullary based on workup, the exact diagnosis was undetermined, leading to a prolonged course of steroid therapy to control anemia.

Extended-duration therapy in advanced non-small-cell lung cancer: promise and pitfalls.

For many years, the cornerstone of treatment for non-small-cell lung cancer (NSCLC) has been third-generation platinum-based chemotherapy. Unfortunately, clinical outcomes with the use of this approach have remained poor, with median survival times of only 8-13 months. In an attempt to improve survival, several therapeutic strategies have recently been investigated, including extended-duration chemotherapy.